David C. Young

University of Utah Health

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do I reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

70%

Pharmacy

100%

Antibiotic Therapy

70%

Cystic Fibrosis Research

70%

Medication Management

40%

Therapeutic Drug Monitoring

40%

Fluid Therapy

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles13

Current State of Pharmacogenomic Implementation Into Care for Persons With Cystic Fibrosis

Article Link

Year:

2025

Cost-Effectiveness Analysis Methods Used in Evaluations of Treatment for Cystic Fibrosis: A Scoping Review

Article Link

Year:

2025

Population pharmacokinetics and target attainment analysis of vancomycin after intermittent dosing in adults with cystic fibrosis

Article Link

Year:

2024

A comparison of aminoglycoside antibiotic serum concentrations collected by peripheral veins and peripherally inserted central catheters in adults with cystic fibrosis

Article Link

Year:

2024

A decade of change: The evolution of pharmacy services at U.S. cystic fibrosis centers

Article Link

Year:

2024

Venous thromboembolism management in people with cystic fibrosis

Article Link

Year:

2024

The pharmacokinetics and pharmacodynamics of continuous infusion vancomycin in adult people with cystic fibrosis

Article Link

Year:

2024

International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists

Article Link

Year:

2023

International consensus recommendations for the use of prolonged‐infusion beta‐lactam antibiotics: Endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists: An executive summary

Article Link

Year:

2023

Assessing the impact of a leadership and advocacy elective course in a college of pharmacy curriculum

Article Link

Year:

2023

Effective pharmacy provider handoff communication for transition of patient care in CF

Article Link

Year:

2023

Pharmacokinetics of intermittent dosed intravenous vancomycin in adult persons with cystic fibrosis

Article Link

Year:

2022

The indispensable role of pharmacy services and medication therapy management in cystic fibrosis

Article Link

Year:

2022

Collaborators8

Lisa Hong

Associate Profesor

Loma Linda University School of Pharmacy

UNITED STATES

Mohammad Alshaer

University of Florida Health

UNITED STATES

T. Joseph Mattingly II

Associate Professor and Vice Chair of Research

University of Utah College of Pharmacy

UNITED STATES

Shannon Gadd

Assistant Professor (Lecturer)

University of Utah

UNITED STATES

Bryn Loutzenhiser

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES

Emma Tillman

Research Associate Professor

Indiana University School of Medicine

UNITED STATES

Robert Bonomo

Case Western Reserve University

UNITED STATES

VENKATA YELLEPEDDI

Associate Professor

University of Utah

UNITED STATES

How do I reach out?

Meet Kite AI